Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines
Authors:
Open Access
- 3 April 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 5 (6) , 1765-1770
Abstract
Erythropoietin (Epo) is a potent inducer of erythropoiesis that is mainly produced in the kidney. Epo is expressed not only in the normal kidney, but also in renal cell carcinomas (RCCs). The aim of the present study was to gain insights into the roles of Epo and its receptor (EpoR) in RCC cells. The study used two RCC cell lines, Caki‑1 and SKRC44, in which Epo and EpoR are known to be highly expressed. The proliferation rate and expression level of hypoxia‑inducible factor‑1α (HIF‑1α) were measured prior to and following Epo treatment and under normoxic and hypoxic conditions. To examine whether HIF‑1α or Epo were involved in cellular proliferation during hypoxia, these proteins were knocked down using small interfering RNA (siRNA) in Caki‑1 and SKRC44 cells. The results demonstrated that Epo enhanced the proliferation of the Caki‑1 and SKRC44 cells. HIF‑1α expression was increased upon the induction of hypoxia in the Caki‑1 cells, but remained unaffected in the SKRC44 cells. The proliferation rate was increased under hypoxic conditions in the Caki‑1 cells, but was decreased in the SKRC44 cells. Under hypoxic conditions, the proliferation of the Caki‑1 cells was significantly reduced by the knock‑down of HIF‑1α or Epo, while the proliferation of the SKRC44 cells was significantly suppressed by the knock‑down of Epo, but not HIF‑1α. In conclusion, these data suggest that the induction of Epo may accelerate the proliferation of the RCC cell lines in either a HIF‑1α‑dependent or ‑independent manner.Keywords
This publication has 46 references indexed in Scilit:
- Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinomaExperimental and Therapeutic Medicine, 2012
- The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinomaInternational Journal of Molecular Medicine, 2010
- Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapyMedical Hypotheses, 2010
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Therapeutic strategy targeting the mTOR–HIF‐1α–VEGF pathway in ovarian clear cell adenocarcinomaPathology International, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Lack of functional erythropoietin receptors of cancer cell linesInternational Journal of Cancer, 2007
- Erythropoietin stimulates proliferation of human renal carcinoma cellsKidney International, 2000
- Erythropoietin: Multiple Physiological Functions and Regulation of BiosynthesisBioscience, Biotechnology, and Biochemistry, 2000